DOCSLIB.ORG

Nothing to Disclose Course Goals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nothing to Disclose Course Goals Nothing to Disclose Pediatric Anterior Segment Conditions Marie I. Bodack,OD, FAAO, FCOVD, Dipl BVPPO Chief, Pediatric Primary Care @ Southern College of Optometry [email protected] Course Goals • To review commonly encountered pediatric anterior segment conditions and their treatment options. • To become comfortable with FDA age guidelines and dosing for ophthalmic medications including orals • To become comfortable in treating pediatric anterior segment disorders • To instill clinical ‘pearls’ for examining children Capillary Hemangioma Capillary Hemangioma • Benign, Soft Tissue Tumor composed of blood • Location: palpebral conjunctiva, upper lid vessels • Bright red mass (superficial) • Most common orbital tumor of childhood • Blanch on pressure • 1/200 births • May bleed spontaneously • Females:Males 3:2 • When crying may enlarge • 30% at birth, 100% by 6 months • Rapid growth in first 12 months of life • Most spontaneously regress by age 5/6 • 30% age 3 • 60% age 4 • 76% age 7 1 Capillary Hemangioma Capillary Hemangioma - Evaluation • Retinoscopy • Concerns • Cardiac/neurological workup & CT/MRI of orbit • Amblyopia 25‐60% • If extensive facial dysmorphia = may be orbital • Occlusion of visual axis by lid • Posterior fossa malformation • Induced corneal astigmatism • Hemangioma • Arterial anomalies • Cardiac defects • Eye abnormalities Capillary Hemangioma - Treatment • Correct refractive error • Treat amblyopia • Steroid injection • Regression in 2‐4 weeks • Oral Beta blocker (propanolol ‐1‐2mg/kg/day) • Mechanism: vasoconstriction, reduction in pro‐ angiogenic signals • Topical timolol maleate 0.25% bid Pope E et al, Topical Timolol Gel for • Surgical excision Infantile Hemangiomas: A Pilot Study. • If severe (cosmesis), amblyopia Arch Dermatol. 2010;146(5):564-565. Ptosis • Unilateral or bilateral • Etiology • Congenital • Acquired • CNIII Palsy • Systemic • Myasthenia Gravis • Trauma • Mechanical • Chalazion/Hordeolum • Hemangioma www.aapos.org 2 Congenital Ptosis • Signs • Levator function • Upper eyelid fold • Concerns • Amblyopia • Deprivation • Induced astigmatism Horner Syndrome Neuroblastoma • Triad • Most common extracranial solid tumor in • Anisocoria dim>bright infants/children • Etiology: disruption of sympathetic nerve • 8‐10% childhood cancers supply • Overall incidence 14/100,000 • Congenital • 85% < age 5 • Iris color lighter • Abdomen • Acquired • Adrenal gland • Neuroblastoma (children) • Can metastasize • Pancost tumor of lung (adults) Ptosis Evaluation Ptosis - Treatment • Observation • Congenital • Frontalis • Treat Amblyopia • Head position • If vision deprivation or cosmetic concerns • Work Up • Surgical correction • Palpebral aperture • Acquired • Upper lid fold • Treat condition • Pupils • Myasthenia • Pearl: Direct ophthalmoscope • Neuroblastoma • Iris color • Ice pack test • MRI abdomen 3 Chalazion/Hordeolum • Treatment • Hot compresses • Topical Medications • Surgery? • Size • Duration • Risk of occlusion amblyopia • Anesthesia • Omega 3s • Oral Antibiotics? Steroid Antibiotic Combination Chronic Treatment • TobraDex (Dexamethasone 0.1%,Tobramycin 0.3%) •Omega 3 • Ages 2+ • gtts (generic) and ung • Adult dose 2‐1000 mg tid • TobraDex ST (Dexamethasone 0.3%, Tobramycin 0.05%) •Pediatric Availability • Ages 2+ • Zylet (Loteprednol 0.5%,Tobramycin 0.3%) • Chewable daily • Blepharitis and lid inflammation 0‐6 years • Maxitrol (Dexamexasone 0.1%,Neomycin,Polymixin B) • Ages 2+ • gtts and ung Macai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336-56. Oral Antibiotics • Erythromycin Ethylsuccinate (EES) – 30‐50mg/kg/day q 6 h – Formulations: 200/400 mg/5ml • Dicloxacillin – 12.5‐50mg/kg/day q 6 h • Amoxicillin – 25‐45mg/kg/day q12 h – 20‐40 mg/kg/day q8h – Formulations: 125/200/250/400 mg/5ml • Tetracycline (Ages 8+) – 250 mg qid 4 Preseptal Cellulitis Preseptal Cellulitis • Infection of eyelid anterior to septum • Examination • 5x more common than orbital • VA • Causes • Pupils • Lid/cutaneous infections • EOMS • Hordeolum/Impetigo • Slit Lamp • HSV/HZV • Treatment • URI/Sinusitis • Oral Medications • Differentials • Referral? • Allergic • Adenovirus (16%) Oral Antibiotics Oral Antibiotics • Amoxicillin, Clavulanate (Augmentin) • 20‐40mg/kg/day q 8h • Formulations: 125/200/250/400mg/5ml •Sulfa Allergy Precautions • Cephalexin (Keflex) – 1st gen •No tetracycline < 8 years • 25‐50mg/kg/day q 6h • Formulations: 125/250/500 mg/5ml •PCN Allergy Precautions • Cefaclor (Ceclor) – 2nd gen st • 20‐40mg/kg/day q 8h • Cross‐reactive to cephalosporins (1 gen)? • Formulations: 125/187/250/375 mg/5ml • Cefdinir (Omnicef) – 3rd gen • 7 mg/kg/day q 12 hr • Formulations: 125/250 mg/5ml • Trimethoprim/Sulfamethaxole (Bactrim) • 8‐12/40‐60mg/kg/day q12h Oral Antibiotics Dosing • PCN Allergy • Cross‐reactivity with cephalosporins • Follow FDA Guidelines • Need to know • Child’s weight in kg • Formulations of medication • 1 tsp = 5ml Apter AJ et al. Am J Med 2006;119, 354 Campagna JD et al. J Emerg Med 2012;42:612 5 Example 5 y/o preseptal: Example 5 y/o preseptal: • 40 lbs = 18.14 kg • 40 lbs = 18.14 kg • Keflex • Augmentin – Dose 25‐50mg/kg/day q 12 h • 20‐40mg/kg/day tid – Formulations 125/250/400mg for 5 ml • Formulations 125/200/250/400mg for 5 ml • Determine min and max mg/day • Determine min and max mg/kg – 453.5 to 907 mg/day • 362.8 to 725.6 mg/day • Therefore : • Therefore : – Can do 250mg q 12 h (500mg daily) • Can do 125 (375 daily) or 200 (600 daily) – Can do 400mg q 12 h (800mg daily) – Can do 1.5 tsp (7.5ml) of 250mg (375) q 12 h (750mg • On Rx: daily) • Giving 5ml tid (15ml/day) for 10 days so dispense • On Rx: 150 ml – 5ml bid x 10 days = 100ml – 7.5ml bid (15ml/day) x 10 days = 150ml Dermoid Cyst • Choroistoma • Congenital • Location: • Conjunctiva = Limbal dermoid • Firm • Color: variable • Concern • Associations • Goldenhar syndrome • Linear nevus sebaceous syndrome Dermoid Cyst Dermoid Cyst - Treatment • Lateral Canthus = Dermolipoma • Monitor • Ddx: prolapsed fat • Correct astigmatism • Amblyopia treatment • Surgical? 6 Allergic Conjunctivitis • Immediate hypersensitivity Type I reaction • Mast cell degranulation • Histamine and leukotriene release • Increased vascular permeability • Seasonal • Year round (Perennial) Ocular Allergy – Antihistamines, Mast Cell Allergic Conjunctivitis Stablizers, & Combination – OTC • Signs: • Ketitofen 0.025% • Bilateral injection • Zaditor • Papillary reaction – bulbar conjunctiva • Alaway • Ages 3+ • Tearing • bid • “Allergic shiner” • Olopatadine 0.1 %0.2% (Pataday) • Symptoms • bid/qd • Ages Antiallergy -Rx Antiallergy -Rx • Azelastine 0.05% (Optivar) • Cromolyn Sodium 4% • Olopatadine 0.1% (Patanol) (Crolom) • Loteprednol etabonate 0.2% (Alrex) • Olopatadine 0.7% (Pazeo) • Ages 4+ • 4‐6 times/day • daily • Safety information in pediatric patients • Vernal • Ages 2+ has not been established • Epinastine 0.05% (Elestat) • Lodoxamide 0.1% (Alomide) • Ages 2+ • Ages 2+ • • 2‐4 times a day up to 3 months Dosing: qid • Bepotastine 1.5% (Bepreve) • Vernal • Ages 2+ • Alcaftadine 0.25% (Lastacaft) Unless stated FDA approved for ages • Daily 3+ and bid • Ages 2+ • Emedastine 0.05% (Emadine) • Up to qid • Cetirizine 0.24% (Zerviate) 7 Vernal Conjunctivitis (VKC) • IgE and T cell mediated • Association: asthma, eczema, seasonal allergic rhinitis • Males>Females (2‐3:1) • Onset <10 years (5‐6 years) • Spring • Symptoms Vernal Conjunctivitis (VKC) Vernal Conjunctivitis - Treatment • Signs • Cobblestone Papillae • Ropy mucus discharge • Mast Cell Stabilizer • Injection • • Cobblestone Papillae Trantas Dots • Cornea • Steroid • Trantas dots • Shield Ulcer • Shield ulcer (5%) • Antibiotic drops • Oval • Superior • Plaque Steroids • Lotoprednol etabonate 0.2% (Alrex) • Lotoprednol etabonate 0.5% (Lotemax) • Drops, ointment and gel • QID • Fluromethalone 0.1% (FML) • Fluromethalone 0.25% (FML Forte) • Ages 2+ • bid to qid • Prednisolone Acetate 1% (Pred Forte) • Use is supported by evidence • Difluprednate (Durezol) • 0 to 3 years of age s/p cat sx Unless stated, no safety information for pediatric patients 8 Bacterial Conjunctivitis Bacterial Conjunctivitis • 50% of cases of acute conjunctivitis • Symptoms • Gigliotti. 1981 J. Pediatrics • Signs • Pathogens • Bulbar/tarsal conjunctival injection • H. flu • Hemorrhagic with H. flu • S. pneumonia • Discharge • 39% concurrent ear infection • Treatment • < 5 years old • Culture? • H. flu • Topical Medication Ointments vs. Drops? Antibiotics - Ointments • Ointment: • Erythromycin 0.5% (Ilotycin) – Neonatal prophylaxis • Easier Installation • Ciprofloxacin 0.3% (Ciloxan) – Up to 6 times/day • 2+ years • Longer lasting • Bacitracin (Ak‐Tracin, Bacticin) • tid x 2 days then bid x 5 – Safety in peds not established • Blurry vision days – 1‐3 times/day • Sulfacetamide 10%, 15% • Better for infants • Tobramycin 0.3% (Tobrex) • Rarely used • Drops: • 2+mos • 2‐3 times/day • No blur • Gentamicin 0.3% (Gentak) • More options – Safety in neonates not established • May sting – 2‐3 times/day – More toxic to cornea • Taste in mouth Antibiotics - Drops Stevens-Johnson • Life‐Threatening Skin Condition • Polymxin B+ • Aminoclycosides • Trimethoprim (Polytrim) • Tobramycin 0.3% Mucus Membranes • 2+mos • Gentamicin 0.3% • Etiology: Hypersensitivity to medications • Dose q3h (6x day) • Sulfacetamide 10%, 15% • Stings • Rarely used 9 Antibiotic Drops - Fluroquinolones • Ages (1+) Antibiotics–Azithromycin (AzaSite) • Q2h x 2 days then qid x 5 days
Load more

Recommended publications
  • Cutaneous Manifestations of Newborns in Omdurman Maternity Hospital
    ﺑﺴﻢ اﷲ اﻟﺮﺣﻤﻦ اﻟﺮﺣﻴﻢ Cutaneous Manifestations of Newborns in Omdurman Maternity Hospital A thesis submitted in the partial fulfillment of the degree of clinical MD in pediatrics and child health University of Khartoum By DR. AMNA ABDEL KHALIG MOHAMED ATTAR MBBS University of Khartoum Supervisor PROF. SALAH AHMED IBRAHIM MD, FRCP, FRCPCH Department of Pediatrics and Child Health University of Khartoum University of Khartoum The Graduate College Medical and Health Studies Board 2008 Dedication I dedicate my study to the Department of Pediatrics University of Khartoum hoping to be a true addition to neonatal care practice in Sudan. i Acknowledgment I would like to express my gratitude to my supervisor Prof. Salah Ahmed Ibrahim, Professor of Peadiatric and Child Health, who encouraged me throughout the study and provided me with advice and support. I am also grateful to Dr. Osman Suleiman Al-Khalifa, the Dermatologist for his support at the start of the study. Special thanks to the staff at Omdurman Maternity Hospital for their support. I am also grateful to all mothers and newborns without their participation and cooperation this study could not be possible. Love and appreciation to my family for their support, drive and kindness. ii Table of contents Dedication i Acknowledgement ii Table of contents iii English Abstract vii Arabic abstract ix List of abbreviations xi List of tables xiii List of figures xiv Chapter One: Introduction & Literature Review 1.1 The skin of NB 1 1.2 Traumatic lesions 5 1.3 Desquamation 8 1.4 Lanugo hair 9 1.5
    [Show full text]
  • Eyelid Conjunctival Tumors
    EYELID &CONJUNCTIVAL TUMORS PHOTOGRAPHIC ATLAS Dr. Olivier Galatoire Dr. Christine Levy-Gabriel Dr. Mathieu Zmuda EYELID & CONJUNCTIVAL TUMORS 4 EYELID & CONJUNCTIVAL TUMORS Dear readers, All rights of translation, adaptation, or reproduction by any means are reserved in all countries. The reproduction or representation, in whole or in part and by any means, of any of the pages published in the present book without the prior written consent of the publisher, is prohibited and illegal and would constitute an infringement. Only reproductions strictly reserved for the private use of the copier and not intended for collective use, and short analyses and quotations justified by the illustrative or scientific nature of the work in which they are incorporated, are authorized (Law of March 11, 1957 art. 40 and 41 and Criminal Code art. 425). EYELID & CONJUNCTIVAL TUMORS EYELID & CONJUNCTIVAL TUMORS 5 6 EYELID & CONJUNCTIVAL TUMORS Foreword Dr. Serge Morax I am honored to introduce this Photographic Atlas of palpebral and conjunctival tumors,which is the culmination of the close collaboration between Drs. Olivier Galatoire and Mathieu Zmuda of the A. de Rothschild Ophthalmological Foundation and Dr. Christine Levy-Gabriel of the Curie Institute. The subject is now of unquestionable importance and evidently of great interest to Ophthalmologists, whether they are orbital- palpebral specialists or not. Indeed, errors or delays in the diagnosis of tumor pathologies are relatively common and the consequences can be serious in the case of malignant tumors, especially carcinomas. Swift diagnosis and anatomopathological confirmation will lead to a treatment, discussed in multidisciplinary team meetings, ranging from surgery to radiotherapy.
    [Show full text]
  • Reconstructive
    RECONSTRUCTIVE Differential Diagnosis of Lower Extremity Enlargement in Pediatric Patients Referred with a Diagnosis of Lymphedema Carolyn C. Schook, B.A. Background: There are many causes for a large lower limb in the pediatric age John B. Mulliken, M.D. group. These children are often mislabeled as having lymphedema, and incor- Steven J. Fishman, M.D. rect diagnosis can lead to improper treatment. The purpose of this study was to Ahmad I. Alomari, M.D. determine the differential diagnosis in pediatric patients referred for lower Frederick D. Grant, M.D. extremity “lymphedema” and to clarify management. Arin K. Greene, M.D., Methods: The authors’ Vascular Anomalies Center database was reviewed be- M.M.Sc. tween 1999 and 2010 for patients referred with a diagnosis of lymphedema of Boston, Mass. the lower extremity. Records were studied to determine the correct cause for the enlarged extremity. Alternative diagnoses, sex, age of onset, and imaging studies were also analyzed. Results: A referral diagnosis of lower extremity lymphedema was given to 170 children; however, the condition was confirmed in only 72.9 percent of patients. Forty-six children (27.1 percent) had another disorder: microcystic/macrocystic lymphatic malformation (19.6 percent), noneponymous combined vascular malformation (13.0 percent), capillary malformation (10.9 percent), Klippel- Trenaunay syndrome (10.9 percent), hemihypertrophy (8.7 percent), posttrau- matic swelling (8.7 percent), Parkes Weber syndrome (6.5 percent), lipedema (6.5 percent), venous malformation (4.3 percent), rheumatologic disorder (4.3 percent), infantile hemangioma (2.2 percent), kaposiform hemangioendothe- lioma (2.2 percent), or lipofibromatosis (2.2 percent).
    [Show full text]
  • Dermatopathology
    Dermatopathology Clay Cockerell • Martin C. Mihm Jr. • Brian J. Hall Cary Chisholm • Chad Jessup • Margaret Merola With contributions from: Jerad M. Gardner • Talley Whang Dermatopathology Clinicopathological Correlations Clay Cockerell Cary Chisholm Department of Dermatology Department of Pathology and Dermatopathology University of Texas Southwestern Medical Center Central Texas Pathology Laboratory Dallas , TX Waco , TX USA USA Martin C. Mihm Jr. Chad Jessup Department of Dermatology Department of Dermatology Brigham and Women’s Hospital Tufts Medical Center Boston , MA Boston , MA USA USA Brian J. Hall Margaret Merola Department of Dermatology Department of Pathology University of Texas Southwestern Medical Center Brigham and Women’s Hospital Dallas , TX Boston , MA USA USA With contributions from: Jerad M. Gardner Talley Whang Department of Pathology and Dermatology Harvard Vanguard Medical Associates University of Arkansas for Medical Sciences Boston, MA Little Rock, AR USA USA ISBN 978-1-4471-5447-1 ISBN 978-1-4471-5448-8 (eBook) DOI 10.1007/978-1-4471-5448-8 Springer London Heidelberg New York Dordrecht Library of Congress Control Number: 2013956345 © Springer-Verlag London 2014 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.
    [Show full text]
  • Copyrighted Material
    Part 1 General Dermatology GENERAL DERMATOLOGY COPYRIGHTED MATERIAL Handbook of Dermatology: A Practical Manual, Second Edition. Margaret W. Mann and Daniel L. Popkin. © 2020 John Wiley & Sons Ltd. Published 2020 by John Wiley & Sons Ltd. 0004285348.INDD 1 7/31/2019 6:12:02 PM 0004285348.INDD 2 7/31/2019 6:12:02 PM COMMON WORK-UPS, SIGNS, AND MANAGEMENT Dermatologic Differential Algorithm Courtesy of Dr. Neel Patel 1. Is it a rash or growth? AND MANAGEMENT 2. If it is a rash, is it mainly epidermal, dermal, subcutaneous, or a combination? 3. If the rash is epidermal or a combination, try to define the SIGNS, COMMON WORK-UPS, characteristics of the rash. Is it mainly papulosquamous? Papulopustular? Blistering? After defining the characteristics, then think about causes of that type of rash: CITES MVA PITA: Congenital, Infections, Tumor, Endocrinologic, Solar related, Metabolic, Vascular, Allergic, Psychiatric, Latrogenic, Trauma, Autoimmune. When generating the differential, take the history and location of the rash into account. 4. If the rash is dermal or subcutaneous, then think of cells and substances that infiltrate and associated diseases (histiocytes, lymphocytes, mast cells, neutrophils, metastatic tumors, mucin, amyloid, immunoglobulin, etc.). 5. If the lesion is a growth, is it benign or malignant in appearance? Think of cells in the skin and their associated diseases (keratinocytes, fibroblasts, neurons, adipocytes, melanocytes, histiocytes, pericytes, endothelial cells, smooth muscle cells, follicular cells, sebocytes, eccrine
    [Show full text]
  • Evaluation and Treatment of Musculoskeletal Vascular Anomalies in Children: an Update and Summary for Orthopaedic Surgeons
    The University of Pennsylvania Orthopaedic Journal 14: 15–24, 2001 © 2001 The University of Pennsylvania Orthopaedic Journal Evaluation and Treatment of Musculoskeletal Vascular Anomalies in Children: An Update and Summary for Orthopaedic Surgeons 1 1 1 2 3 4 J.A. MCCARRON, D.R. JOHNSTON, B.G. HANNA, M.D., D.W. LOW, M.D., J.S. MEYER, M.D., M. SUCHI, M.D., PH.D., 1 AND J.P. DORMANS, M.D. Abstract: The majority of vascular anomalies can be catego- Accurate nomenclature for vascular anomalies is central rized as either hemangiomas or vascular malformations. Heman- to understanding the etiology of these lesions and to devel- giomas are the most common benign soft tissue tumors of child- oping an appropriate treatment plan [7,14–16,18], however, hood, occurring in 4%–10% of children [16]. Vascular malforma- tions represent a separate group of congenital vascular anomalies. much of the current terminology used to categorize vascular Both hemangiomas and vascular malformations are often located anomalies is inconsistent. The biological classification sys- deep to the deep fascia in the trunk and extremities of children and tem, which was developed by Mulliken and Glowacki in can present with signs and symptoms similar to that of malignant 1982, offers a clear, effective method of describing these soft tissue tumors such as rabdomyosarcomas. Given the high lesions [17]. Children with hemangiomas, are usually re- prevalence of vascular anomalies in the pediatric population, and the need to distinguish them quickly and accurately from other soft ferred to a plastic surgeon for observation or treatment is tissue tumors, any orthopaedic surgeon treating children must have usually the best option.
    [Show full text]
  • Nova Scotia Atlee Perinatal Database Coding Manual 19Th Edition (Version 19.0.0)
    Nova Scotia Atlee Perinatal Database Coding Manual 19th Edition (Version 19.0.0) April 2015 Table of Contents INDEX FOR ADMISSION INFORMATION 1 INDEX FOR ROUTINE INFORMATION – DELIVERED ADMISSION 2 INDEX FOR ROUTINE INFORMATION – LABOUR 4 INDEX FOR ROUTINE INFORMATION – INFANT 5 INDEX FOR ROUTINE INFORMATION – UNDELIVERED ADMISSION 7 INDEX FOR ROUTINE INFORMATION – POSTPARTUM ADMISSION 8 INDEX FOR ROUTINE INFORMATION – NEONATAL ADMISSION 9 ADULT RCP CODES 10 INFANT RCP CODES 11 LISTING OF HOSPITALS 13 LISTING OF HOSPITALS 14 ADMISSION INFORMATION 18 DELIVERED ADMISSION 28 Routine Information – Delivered Admission 28 Routine Information – Labour 58 Routine Information – Infant 79 UNDELIVERED ADMISSION 94 Routine information – undelivered 94 POSTPARTUM ADMISSIONS 104 Routine Information – Postpartum Admission 104 NEONATAL ADMISSIONS 112 Routine Information – Neonatal Admissions 112 ADULT RCP CODES 124 INFANT RCP CODES 144 INDEX OF MATERNAL DISEASES AND PROCEDURES 180 INDEX OF NEONATAL DISEASES AND PROCEDURES 196 INDEX FOR ADMISSION INFORMATION Admission date /time .........................................................................................................19 Admission process status ...................................................................................................27 Admission type ..................................................................................................................19 A/S/D number ....................................................................................................................20
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,359,748 B1 Drugge (45) Date of Patent: Apr
    USOO7359748B1 (12) United States Patent (10) Patent No.: US 7,359,748 B1 Drugge (45) Date of Patent: Apr. 15, 2008 (54) APPARATUS FOR TOTAL IMMERSION 6,339,216 B1* 1/2002 Wake ..................... 250,214. A PHOTOGRAPHY 6,397,091 B2 * 5/2002 Diab et al. .................. 600,323 6,556,858 B1 * 4/2003 Zeman ............. ... 600,473 (76) Inventor: Rhett Drugge, 50 Glenbrook Rd., Suite 6,597,941 B2. T/2003 Fontenot et al. ............ 600/473 1C, Stamford, NH (US) 06902-2914 7,092,014 B1 8/2006 Li et al. .................. 348.218.1 (*) Notice: Subject to any disclaimer, the term of this k cited. by examiner patent is extended or adjusted under 35 Primary Examiner Daniel Robinson U.S.C. 154(b) by 802 days. (74) Attorney, Agent, or Firm—McCarter & English, LLP (21) Appl. No.: 09/625,712 (57) ABSTRACT (22) Filed: Jul. 26, 2000 Total Immersion Photography (TIP) is disclosed, preferably for the use of screening for various medical and cosmetic (51) Int. Cl. conditions. TIP, in a preferred embodiment, comprises an A6 IB 6/00 (2006.01) enclosed structure that may be sized in accordance with an (52) U.S. Cl. ....................................... 600/476; 600/477 entire person, or individual body parts. Disposed therein are (58) Field of Classification Search ................ 600/476, a plurality of imaging means which may gather a variety of 600/162,407, 477, 478,479, 480; A61 B 6/00 information, e.g., chemical, light, temperature, etc. In a See application file for complete search history. preferred embodiment, a computer and plurality of USB (56) References Cited hubs are used to remotely operate and control digital cam eras.
    [Show full text]
  • Osteopathic Journal Feb 2006 6
    Journal of the AMERICAN OSTEOPATHIC COLLEGE OF DERMATOLOGY 2005-2006 Officers Journal of the President: Richard A. Miller, DO President-Elect: Bill V. Way, DO American First Vice-President: Jay S. Gottlieb, DO Second Vice-President: Donald K. Tillman, DO Third Vice-President: Marc I. Epstein, DO Osteopathic Secretary-Treasurer: Jere J. Mammino, DO Immediate Past President: Ronald C. Miller, DO College Trustees: David W. Dorton, DO Bradley P. Glick, DO of Dermatology Daniel S. Hurd, DO Jeffrey N. Martin, DO Executive Director: Rebecca Mansfield, MA Editors Jay S. Gottlieb, D.O., F.O.C.O.O. Stanley E. Skopit, D.O., F.A.O.C.D. Associate Editor James Q. Del Rosso, D.O., F.A.O.C.D. Editorial Review Board Ronald Miller, D.O. Eugene Conte, D.O. Evangelos Poulos, M.D. Stephen Purcell, D.O. AOCD • 1501 E. Illinois • Kirksville, MO 63501 Darrel Rigel, M.D. 800-449-2623 • FAX: 660-627-2623 www.aocd.org Robert Schwarze, D.O. Andrew Hanly, M.D. COPYRIGHT AND PERMISSION: written permission must be Michael Scott, D.O. obtained from the Journal of the American Osteopathic College of Dermatology for copying or reprinting text of more than half page, Cindy Hoffman, D.O. tables or figures. Permissions are normally granted contingent upon Charles Hughes, D.O. similar permission from the author(s), inclusion of acknowledgement Bill Way, D.O. of the original source, and a payment of $15 per page, table or figure of reproduced material. Permission fees are waived for authors Daniel Hurd, D.O. wishing to reproduce their own articles.
    [Show full text]
  • A Comparative Histopathological and Immunohistochemically Study of Capillary
    Int J Oral-Med Sci 9(3):241-251,2011 Original Article A Comparative Histopathological and Immunohistochemically Study of Capillary Hemangioma,Pyogenic Granuloma and Cavernous Hemangioma in the Oral Region: with Special Reference to Vascular Proliferation Factors Naoko Kawachi Nihon University Graduate School of Dentistry at Matsudo,Oral Surgery,Matsudo,Chiba 271-8587,Japan Correspondence to: Naoko Kawachi,DDS Capillary hemangioma, pyogenic granuloma and cavernous heman- E-mail: wakatakenao＠yahoo.co.jp gioma,benign vascular lesions affect in the oral regions.There have been some studies of them,but their pathological status is still contro- versial.The aim of the present study was to reveal the characteristic histopathological and immunohistochemical features such as cell pro- liferation activity, vascular proliferation factors and mesenchymal marker of these lesions in order to understand the pathological status of them.In histopathological findings of the present study,capillary hemangioma consisted of proliferating capillaries having endothelial cells and ovoid or spindle cells and associated with mast cells and lobular structures circumscribed with PAS-positive matrices. Pyogenic granuloma exhibited proliferation of the capillaries having endothelial cells and a few perivascular mesenchymal ovoid or spindle cells beneath erosive and ulcerative lesions and inflammatory changes. Cavernous hemangioma was composed of remarkably dilated and hyperplasic blood vessels. Immunohistochemically, Ki-67 labeling index of capillary hemangioma and
    [Show full text]
  • Vascular Malformations and Tumors Continues to Grow Overview Table Vascular Anomalies
    ISSVA classification for vascular anomalies © (Approved at the 20th ISSVA Workshop, Melbourne, April 2014, last revision May 2018) This classification is intended to evolve as our understanding of the biology and genetics of vascular malformations and tumors continues to grow Overview table Vascular anomalies Vascular tumors Vascular malformations of major named associated with Simple Combined ° vessels other anomalies Benign Capillary malformations CVM, CLM See details See list Lymphatic malformations LVM, CLVM Locally aggressive or borderline Venous malformations CAVM* Arteriovenous malformations* CLAVM* Malignant Arteriovenous fistula* others °defined as two or more vascular malformations found in one lesion * high-flow lesions A list of causal genes and related vascular anomalies is available in Appendix 2 The tumor or malformation nature or precise classification of some lesions is still unclear. These lesions appear in a separate provisional list. For more details, click1 on Abbreviations used the underlined links Back to ISSVA classification of vascular tumors 1a Type Alt overview for previous view Benign vascular tumors 1 Infantile hemangioma / Hemangioma of infancy see details Congenital hemangioma GNAQ / GNA11 Rapidly involuting (RICH) * Non-involuting (NICH) Partially involuting (PICH) Tufted angioma * ° GNA14 Spindle-cell hemangioma IDH1 / IDH2 Epithelioid hemangioma FOS Pyogenic granuloma (also known as lobular capillary hemangioma) BRAF / RAS / GNA14 Others see details * some lesions may be associated with thrombocytopenia
    [Show full text]
  • Histopathological Spectrum of Pediatric Skin Biopsies in a Rural Setup
    Original Research Article http://doi.org/10.18231/j.ijpo.2019.054 Histopathological spectrum of pediatric skin biopsies in a rural setup Shruthi N Shetageri1, Roopa A N2*, Raja Parthiban3, Rekha T P4, Shruthi H5 1Assistant Professor, 2Professor, 3Professor and HOD, 4,5Postgraduate, Dept. of Pathology, MVJ Medical College & Research Hospital, Hoskote, Bengaluru, Karnataka, India *Corresponding Author: Roopa A N Email: [email protected] Received: 31st October, 2018 Accepted: 11th December, 2018 Abstract Prevalence of pediatric skin disorders vary worldwide. In India, geographic variations in pediatric skin disorders is noted by numerous authors from different parts of the country. Dermatoses in children are much more influenced by socioeconomic status, climatic exposure, dietary habits and external environment as compared to adult skin disorders. Aims and Objectives: The present study was aimed at determining the spectrum of pediatric dermatopathological lesions and correlate the clinical and histopathological diagnosis over a period of 2 years in a tertiary care hospital in a rural setup. Results: Pediatric skin biopsies constituted 12.41% of all the skin biopsies received at our laboratory during the study period. Study consisted of 115 cases ranging from 1 to 18 years of age with a mean age of 12.02 years. A slight female preponderance (53.91%) was noted. The Biopsies received were categorized into various age groups as follows: Infants, n = 2(1.73%); toddler, n= 4(3.47%); preschool, n = 14(12.17%); school, n= 40 (34.78%) and adolescence, n= 55(47.82%). Papulosquamous diseases, n= 36(31.30%) were the most common cause of skin disorders followed by Genodermatosis (12.17%).
    [Show full text]